Summary.
Propargylamine derivatives, rasagiline and (–)deprenyl, are anti-Parkinson agents and protect neurons from cell death as shown by in vivo and in vitro experiments. The studies on the chemical structure-activity relationship proved that the propargyl moiety is essentially required for the neuroprotective function. In this paper, neuroprotective activity of free N-propargylamine was studied using SH-SY5Y cells expressing only type A monoamine oxidase (MAO) against apoptosis induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. N-Propargylamine prevented apoptosis, whereas N-methylpropargylamine and propiolaldehyde did not. N-Propargylamine stabilized mitochondrial membrane potential and induced anti-apoptotic Bcl-2 at 1 µM–10 nM. N-Propargylamine inhibited MAO-A in competition to substrate with the apparent Ki value of 28 µM, which was significantly higher than the concentration required for neuroprotection. It indicates that MAO inhibition is not prerequisite for the protective function of N-propargylamine. The anti-apoptotic function of N-propargylamine is discussed in terms of neuroprotection by propargylamines in neurodegenerative diseases, including Parkinson’s disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Y Akao W Maruyama S Shimizu H Yi Y Nakagawa M Shamoto-Nagai MBH Youdim Y Tsujimoto M Naoi (2002a) ArticleTitleMitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82 913–923 Occurrence Handle10.1046/j.1471-4159.2002.01047.x Occurrence Handle1:CAS:528:DC%2BD38XmsF2hurc%3D
Y Akao W Maruyama H Yi M Shamoto-Nagai MBH Youdim M Naoi (2002b) ArticleTitleAn anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326 10510–10518 Occurrence Handle10.1016/S0304-3940(02)00332-4
O Bar-Am A Yogev-Falach T Amit Y Sagi MBH Youdim (2004) ArticleTitleRegulation of protein kinase C by the anti-parkinson drug, MAO-B inhibitor rasagiline and its derivatives, in vivo. J Neurochem 89 1119–1125 Occurrence Handle15147504 Occurrence Handle10.1111/j.1471-4159.2004.02425.x Occurrence Handle1:CAS:528:DC%2BD2cXkvFOktbw%3D
MM Bradford (1976) ArticleTitleA rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72 248–254 Occurrence Handle942051 Occurrence Handle10.1016/0003-2697(76)90527-3 Occurrence Handle1:CAS:528:DyaE28XksVehtrY%3D
MC Carrillo C Minami K Kitani W Maruyama K Ohashi T Yamamoto M Naoi S Kanai MB Youdim (2000) ArticleTitleEnhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67 577–585 Occurrence Handle10993123 Occurrence Handle1:CAS:528:DC%2BD3cXksVKjurg%3D
EG DeMaster FN Shirota HT Nagasawa (1981) ArticleTitleRole of propiolaldehyde and other metabolites in the pargyline inhibition of rat liver aldehyde dehydrogenase. Biochem Pharmacol 35 1481–1489
S Desagher A Osen-Sand A Nichols R Eskes S Montessuit S Lauper K Maundrell B Antonsson J-C Martinou (1999) ArticleTitleBid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144 891–901 Occurrence Handle10085289 Occurrence Handle10.1083/jcb.144.5.891 Occurrence Handle1:CAS:528:DyaK1MXhs1yqtbY%3D
A Eckert B Steiner C Marques S Leutz H Roming C Haass WE Muller (2001) ArticleTitleElevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 64 183–192 Occurrence Handle11288146 Occurrence Handle10.1002/jnr.1064 Occurrence Handle1:CAS:528:DC%2BD3MXislWnu7w%3D
JPM Finberg T Takeshima JM Johnson JW Commissiong (1998) ArticleTitleIncreased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. NeuroReport 9 701–707
J Knoll Z Ecsery K Magyar E Satory (1978) ArticleTitleNovel (–)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol 27 1739–1747 Occurrence Handle708454 Occurrence Handle10.1016/0006-2952(78)90550-6 Occurrence Handle1:CAS:528:DyaE1MXhsl2qsrg%3D
M Kraml (1965) ArticleTitleA rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14 1684–1686
K Magyar B Szende J Lengyel K Tekes (1996) ArticleTitleThe pharmacology of B-type selective monoamine oxidase inhibitors: milestones in (–)-deprenyl research. J Neural Transm (Suppl) 48 29–43 Occurrence Handle1:CAS:528:DyaK2sXmsF2nt7o%3D
W Maruyama M Naoi (1999) ArticleTitleNeuroprotection by (–)-deprenyl and related compounds. Mech Ageing Dev 111 189–200 Occurrence Handle10656536 Occurrence Handle10.1016/S0047-6374(99)00066-4 Occurrence Handle1:CAS:528:DyaK1MXns1ahsLo%3D
W Maruyama Y Akao MBH Youdim M Naoi (2000) ArticleTitleNeurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm (Suppl) 60 171–186
W Maruyama Y Akao MBH Youdim BA Davis M Naoi (2001a) ArticleTitleTransfection-forced Bcl-2 overexpression and anti-Parkinson drug, rasagiline, prevent nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78 727–735 Occurrence Handle10.1046/j.1471-4159.2001.00448.x Occurrence Handle1:CAS:528:DC%2BD3MXmt1egs70%3D
W Maruyama AA Boulton BA Davis P Dostert M Naoi (2001b) ArticleTitleEnantio-specific induction of apoptosis by an endogenous neurotoxin N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J Neural Transm 108 11–24 Occurrence Handle10.1007/s007020170093 Occurrence Handle1:CAS:528:DC%2BD3MXivVKku7o%3D
W Maruyama MBH Youdim M Naoi (2001c) ArticleTitleAntiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann NY Acad Sci 939 320–329 Occurrence Handle1:CAS:528:DC%2BD3MXlsV2ksL0%3D
W Maruyama T Takahashi MBH Youdim M Naoi (2002) ArticleTitleThe anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109 467–481 Occurrence Handle11956966 Occurrence Handle10.1007/s007020200038 Occurrence Handle1:CAS:528:DC%2BD38XltFagurs%3D
W Maruyama M Weinstock MBH Youdim M Nagai M Naoi (2003) ArticleTitleAnti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine inhibitor. Neurosci Lett 341 233–236 Occurrence Handle12697291 Occurrence Handle10.1016/S0304-3940(03)00211-8 Occurrence Handle1:CAS:528:DC%2BD3sXivFCqt7Y%3D
W Maruyama A Nitta M Shamoto-Nagai Y Hirata Y Akao M Youdim S Furukawa T Nabeshima M Naoi (2004) ArticleTitleN-Propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44 393–400 Occurrence Handle14687604 Occurrence Handle10.1016/j.neuint.2003.08.005 Occurrence Handle1:CAS:528:DC%2BD3sXpvVWnsLk%3D
C Mytilineou PM Radcliffe CW Olanow (1997) ArticleTitleL-(–)-Desmethylselegiline, a metabolite of selegiline [L-(–)-deprenyl], protects mesencephalic dopamine neurons from excitoxicity in vitro. J Neurochem 68 434–435 Occurrence Handle8978757 Occurrence Handle1:CAS:528:DyaK2sXhslOqtQ%3D%3D
J Nagy JL Salach (1981) ArticleTitleIdentity of the active site flavin-peptide fragments from the human “A”-form and the bovine “B”-form of monoamine oxidase. Arch Biochem Biophys 208 388–394 Occurrence Handle7259196 Occurrence Handle10.1016/0003-9861(81)90523-3 Occurrence Handle1:CAS:528:DyaL3MXitVCms7w%3D
M Naoi W Maruyama (2001) ArticleTitleFuture of neuroprotection in Parkinson’s disease. Parkinsonism Relat Disord 8 139–145 Occurrence Handle11489679 Occurrence Handle10.1016/S1353-8020(01)00028-1 Occurrence Handle1:STN:280:DC%2BD383ovFWrug%3D%3D
M Naoi W Maruyama Y Akao H Yi (2002a) ArticleTitleMitochondria determine the survival and death in apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J Neural Transm 109 607–621 Occurrence Handle10.1007/s007020200050 Occurrence Handle1:CAS:528:DC%2BD38XmtVCqsrs%3D
M Naoi W Maruyama Y Akao H Yi (2002b) ArticleTitleDopamine-derived endogenous N-methyl-(R)-salsolinol. Its role in Parkinson’s disease. Neurotoxicol Teratol 24 579–591 Occurrence Handle1:CAS:528:DC%2BD38XmsVCit74%3D
M Naoi W Maruyama MB Youdim P Yu AA Boulton (2003) ArticleTitleAnti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 11 175–181 Occurrence Handle15035819 Occurrence Handle10.1163/156856003765764344 Occurrence Handle1:CAS:528:DC%2BD3sXmt1Wmsro%3D
InstitutionalAuthorNameParkinson Study Group (2002) ArticleTitleA controlled trial of rasagiline in early Parkinson disease. Arch Neurol 59 1037–1943 Occurrence Handle10.1001/archneur.59.12.1937
InstitutionalAuthorNameParkinson Study Group (2004) ArticleTitleA controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 561–566 Occurrence Handle10.1001/archneur.61.4.561
BM Ravina SC Fagan RG Hart CA Hovinga DD Murphy TM Dawson JR Marler (2003) ArticleTitleNeuroprotective agents for clinical trials in Parkinson’s disease. A systematic assessment. Neurol 60 1234–1240 Occurrence Handle1:STN:280:DC%2BD3s7ovVKitg%3D%3D
P Riederer L Lachenmayer (2003) ArticleTitleSelegiline’s neuroprotective capacity revisited. J Neural Transm 110 1273–1278 Occurrence Handle14628191 Occurrence Handle10.1007/s00702-003-0083-x Occurrence Handle1:CAS:528:DC%2BD3sXptVyqsr0%3D
FN Shirota EG DeMaster HT Nagasawa (1979) ArticleTitlePropioladehyde, a pargyline metabolite that irreversibly inhibits aldehyde dehydrogenase. Isolation from a hepatic microsomal system. J Med Chem 22 463–464 Occurrence Handle458796 Occurrence Handle10.1021/jm00191a001 Occurrence Handle1:CAS:528:DyaE1MXhs1Wqur8%3D
WG Tatton WYL Ju DP Holland C Tai M Kwan (1994) ArticleTitle(–)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63 1572–1575 Occurrence Handle7931312 Occurrence Handle1:CAS:528:DyaK2cXmt1WrsLg%3D
S Teitel J O’Brien A Brossi (1972) ArticleTitleAlkaloids in mammalian tissue II. Synthesis of (+) and (−) substituted 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. J Med Chem 15 845–846 Occurrence Handle5044300 Occurrence Handle10.1021/jm00278a014 Occurrence Handle1:CAS:528:DyaE38XltV2htLs%3D
Y Tsujimoto S Shimizu (2000) ArticleTitleBcl-2 family: life-or-death switch. FEBS Lett 466 6–10 Occurrence Handle10648802 Occurrence Handle10.1016/S0014-5793(99)01761-5 Occurrence Handle1:CAS:528:DC%2BD3cXltVCksQ%3D%3D
M Vila S Przedborski (2003) ArticleTitleTargeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4 365–375 Occurrence Handle12728264 Occurrence Handle10.1038/nrn1100 Occurrence Handle1:CAS:528:DC%2BD3sXjtlalsb4%3D
O Weinreb O Bar-Am T Amit O Chillag-Talmor MBH Youdim (2004) ArticleTitleNeuroprotection via pro-survival PKC isoforms associated with Bcl-2 family members. FASEB J 18 2033–2043
M Yogev-Falach T Amit O Bar-Am M Weinstock MB Youdim (2002) ArticleTitleInvolvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16 1674–1676 Occurrence Handle12206996 Occurrence Handle1:CAS:528:DC%2BD38XnvFWgu7s%3D
M Yogev-Falach T Amit O Bar-Am MBH Youdim (2003) ArticleTitleThe importance of propargylamine moiety in the ant-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17 2325–2327 Occurrence Handle14525944 Occurrence Handle1:CAS:528:DC%2BD3sXpvVSnu7k%3D
MBH Youdim A Gross JPM Finberg (2001a) ArticleTitleRasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132 500–506 Occurrence Handle10.1038/sj.bjp.0703826 Occurrence Handle1:CAS:528:DC%2BD3MXht1Sgu7o%3D
MB Youdim A Wadia W Tatton M Weinstock (2001b) ArticleTitleThe anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939 450–458 Occurrence Handle1:CAS:528:DC%2BD3MXlsV2ksbo%3D
MBH Youdim T Amit M Falach-Yogev OB Am W Maruyama M Naoi (2003) ArticleTitleThe essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol 66 1635–1641 Occurrence Handle14555244 Occurrence Handle10.1016/S0006-2952(03)00535-5 Occurrence Handle1:CAS:528:DC%2BD3sXnvVeqsLk%3D
PH Yu BA Davis AA Boulton (1992) ArticleTitleAliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 35 3705–3713 Occurrence Handle1433183 Occurrence Handle1:CAS:528:DyaK38XlslSktrc%3D
PH Yu BA Davis AA Boulton (1993) ArticleTitleEffect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity. Biochem Pharmacol 46 753–757 Occurrence Handle8363648 Occurrence Handle10.1016/0006-2952(93)90564-D Occurrence Handle1:CAS:528:DyaK2cXht1w%3D
P Yu BA Davis DA Durden A Barber I Terleckyj WG Nicklas AA Boulton (1994) ArticleTitleNeurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. J Neurochem 62 697–704 Occurrence Handle8294932 Occurrence Handle1:CAS:528:DyaK2cXhsFels74%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yi, H., Maruyama, W., Akao, Y. et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113, 21–32 (2006). https://doi.org/10.1007/s00702-005-0299-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-005-0299-z